CABA

CABA

USD

Cabaletta Bio Inc. Common Stock

$2.700-0.160 (-5.594%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$2.860

Hoch

$2.970

Tief

$2.630

Volumen

3.67M

Unternehmensfundamentaldaten

Marktkapitalisierung

247.0M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

3.63M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $0.986Aktuell $2.700Hoch $5.46

Ähnliche Nachrichten

GlobeNewswire

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis

Mehr anzeigen
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Mehr anzeigen
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio with a Overweight and raises the price target from $15 to $30.

Mehr anzeigen
Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30
GlobeNewswire

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no

Mehr anzeigen
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.